PharmaEssentia reports 55% two-year BESREMi persistence in polycythemia vera
PharmaEssentia will present six studies examining treatment gaps and real-world BESREMi use in essential thrombocythemia and polycythemia vera. The findings include 55% two-year treatment persistence in first-line PV users and new molecular response data from Asian patient populations.